Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

@article{Orgogozo2003SubacuteMI,
  title={Subacute meningoencephalitis in a subset of patients with AD after A$\beta$42 immunization},
  author={J. -M. Orgogozo and Sid Gilman and Jean-François Dartigues and Bernard Laurent and Mich{\'e}le Puel and Louis C. Kirby and Pierre Jouanny and Bruno Dubois and L Eisner and Stephen S. Flitman and Bernard François Michel and Merc{\`e} Boada and Ana Frank and Christoph Hock},
  journal={Neurology},
  year={2003},
  volume={61},
  pages={46 - 54}
}
Background: AD is characterized by cerebral deposition of β-amyloid plaques with amyloid β-peptide (Aβ) 42 as the major peptide constituent, along with neurofibrillary tangles and neuronal loss. In transgenic mice, active immunization against Aβ42 removes these plaques and improves cognitive function. A Phase I study in AD patients demonstrated good safety and tolerability of multiple injections of aggregated Aβ42 (AN1792) with QS-21 as adjuvant. Methods: Three hundred seventy-two patients with… Expand
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
TLDR
This phase IIa immunotherapy trial of AN1792(QS-21) in patients with mild to moderate Alzheimer disease (AD) that was interrupted because of meningoencephalitis provides an indication that Aβ immunotherapy may be useful in Alzheimer disease. Expand
Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease
TLDR
A dissociation between brain volume loss and cognitive function was observed in AN1792/QS-21 antibody responders and the reasons for this remain unclear but include the possibility that volume changes were due to amyloid removal and associated cerebral fluid shifts. Expand
The biochemical aftermath of anti-amyloid immunotherapy
TLDR
Although in some cases the apparent removal of amyloid plaques by AN-1792 was impressive, proportionate alterations in the clinical progression of AD were not evident, suggesting the likelihood that these deposits alone are not the underlying cause of dementia. Expand
Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD
TLDR
AN1792 + QS-21 elicited a positive antibody response to Aβ42 in more than half of this elderly study population, and Disability Assessment for Dementia scores showed less decline among active compared with control patients at week 84 (p = 0.002). Expand
Intramembranous Fragment of Amyloid-β: A Potential Immunogen for Alzheimer’s Disease Immunotherapy
TLDR
Vaccination with intramembranous fragment of amyloid-β (IF-Aβ) is used to immunize Kunming mice for up to 2.5 months and it is concluded that vaccination with IF-A β may be a potentially safe and effective treatment for AD. Expand
Absence of β-amyloid deposits after immunization in Alzheimer disease with lewy body dementia
TLDR
In this Lewy body variant case, with globally stable functional and cognitive features, Aβ immunization resulted in a significant clearance of amyloid deposits, with remaining tau and synuclein pathological features in the brain. Expand
Setback for an Alzheimer’s disease vaccine
TLDR
The phase II trial of one anti-Aβ therapy, Aβ immunization, and the details of the meningoencephalitis-related complications that developed in 6% of the patients are reported on. Expand
Transcutaneous β-amyloid immunization reduces cerebral β-amyloid deposits without T cell infiltration and microhemorrhage
TLDR
T.c. immunization constitutes an effective and potentially safe treatment strategy for AD and reduction in cerebral amyloidosis was not associated with deleterious side effects, including brain T cell infiltration or cerebral microhemorrhage. Expand
Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders
TLDR
The hypothesis that Aβ immunotherapy may have long-term functional benefits is supported after patients defined as responders in the phase 2a study maintained low but detectable, sustained anti-AN1792 antibody titers and demonstrated significantly reduced functional decline compared with placebo-treated patients. Expand
Immunotherapy as treatment for Alzheimer’s disease
TLDR
Results from the passive vaccination AD clinical trials that are currently underway will provide invaluable information about both the effectiveness of newly improved anti-Aβ vaccines in clinical treatment, as well as the role of the Aβ peptide in the pathogenesis of the disease. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 45 REFERENCES
Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report
TLDR
It is suggested that the immune response generated against the peptide elicited clearance of Aβ plaques in this patient and strongly resemble the changes seen after Aβ immunotherapy in mouse models of AD. Expand
Acute disseminated encephalomyelitis in adults: a reappraisal of clinical, CSF, EEG, and MRI findings
TLDR
The EEG as an investigation of brain function can be crucial in establishing the organic nature of disease and abnormal MRI should not be considered mandatory in adult ADEM. Expand
Clinical and neuroradiologic features of acute disseminated encephalomyelitis in children
TLDR
The authors suggest that a viral prodrome, early-onset ataxia, high lesion load on MRI, involvement of the deep gray matter, and absence of oligoclonal bands are more indicative of ADEM. Expand
Acute disseminated encephalomyelitis: A follow-up study of 40 adult patients
TLDR
No useful diagnostic criteria is found for the differentiation of a first episode of MS from monophasic ADEM, and the term ADEM may still be employed as a description of a clinical syndrome, but should not be used as a distinct entity until reliable diagnostic criteria have been developed. Expand
Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease
TLDR
Findings indicate that vaccination of AD patients with Aβ42 induces antibodies that have a high degree of selectivity for the pathogenic target structures, and whether vaccination to produce antibodies against β-amyloid will halt the cognitive decline in AD will depend upon clinical assessments over time. Expand
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice.
TLDR
It is reported that immunization in transgenic APP mice for 7 months with a soluble nonamyloidogenic, nontoxic Abeta homologous peptide reduced cortical and hippocampal brain amyloid burden and brain levels of soluble Abeta1-42 were reduced, indicating reduced inflammation in these animals. Expand
The spectrum of postinfectious encephalomyelitis
TLDR
The breadth of the clinical spectrum of postinfectious encephalitis/encephalomyelitis is demonstrated, including the cerebral hemisphere, basal ganglia, brainstem and cerebellum, which indicates a longer clinical course and more neurological sequelae than group I patients. Expand
Prevention and Reduction of AD‐type Pathology in PDAPP Mice Immunized with Aβ1–42
TLDR
Aβ immunization appears to increase clearance of amyloid plaques, and may therefore be a novel and effective approach for the treatment of AD. Expand
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
TLDR
It is reported that immunization of the young animals essentially prevented the development of β-amyloid-plaque formation, neuritic dystrophy and astrogliosis, and treatment of the older animals markedly reduced the extent and progression of these AD-like neuropathologies. Expand
Nonoverlapping but synergetic tau and APP pathologies in sporadic Alzheimer’s disease
TLDR
The spatial mismatch between amyloid ß-precursor protein (APP) and tau pathologies in cortical brain areas demonstrates that neurodegeneration is not a direct consequence of extracellular A&bgr; neurotoxicity, and should be the main target for the early biological diagnosis of AD and modeling. Expand
...
1
2
3
4
5
...